Scancell Holdings PLC (LSE:SCLP, FRA:SCP) (LON:SCLP) said Professor Lindy Durrant has been appointed chief executive of the drug developer – taking over from outgoing CEO Cliff Holloway
The company’s founder and chief scientific officer will take on the job with immediate effect, having previously served as co-CEO with former boss Richard Goodfellow before he took on sole responsibility for the position prior to Holloway's appointment to the role.
Departing CEO Holloway said: "Since I joined Scancell in early 2018 we've built and financed the company to the point where it has a strong and diverse pipeline and it can now embark on its next phase of growth.
“I'm proud to have led Scancell during this pivotal time. The company is now stronger than ever and I look forward to following its continued progress."